-

DiaMedica Therapeutics to Participate at Upcoming Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the company will participate in three upcoming investor conferences. Details of the company’s participation are as follows:

  • 33rd Annual Roth Conference
    Details: DiaMedica Therapeutics management will deliver a fireside chat and participate in 1-on-1 meetings
    Company conference participation date: March 15th, 2021
  • Oppenheimer’s 31st Annual Healthcare Conference
    Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
    Company conference participation date: March 16th, 2021
  • Maxim’s Emerging Growth Conference
    Details: DiaMedica Therapeutics management will deliver a corporate presentation and participate in 1-on-1 meetings
    Company conference participation date: March 17th, 2021

For more information or to schedule a one-on-one meeting with management, please contact your conference representative.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company focused on developing novel treatments to improve the lives of patients with neurological and chronic kidney diseases. To learn more about DiaMedica, please visit www.diamedica.com.

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

Industry:

DiaMedica Therapeutics Inc.

NASDAQ:DMAC
Release Versions
English

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

More News From DiaMedica Therapeutics Inc.

DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in three upcoming investment bank conferences. Details TD Cowen 46th Annual Healthcare Conference Boston, Massachusetts  Fireside chat with Rick Pauls, CEO, and Julie Krop, M.D., Chief Medical Officer, on Monday, Mar...

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on January 15, 2026, it granted options to purchase an aggregate of 50,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in December 2025. The stock options were a material inducement to the emplo...

DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS), today announced completion of a productive in-person pre-IND meeting with the United States Food and Drug Administration (FDA) for a planned study evaluating DM199 in preeclampsia. Minutes from the meeting affirmed the FDA’s request for one additional non-clinical, 1...
Back to Newsroom